Results presented today at The International Liver Congress 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These ...
Apr 25, 2015
0
6
Results presented today at The International Liver Congress 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ...
Apr 25, 2015
0
4
Results presented today at The International Liver Congress 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high ...
Apr 23, 2015
0
6
Researchers at Penn Medicine, in collaboration with a multi-center international team, have shown that a protease inhibitor, simeprevir, a once a day pill, along with interferon and ribavirin has proven as effective in treating ...
Dec 9, 2014
1
0
(HealthDay)—For patients with chronic hepatitis C virus genotype 1 (HCV GT-1) infection who are ineligible for interferon therapy, and who relapsed after sofosbuvir and ribavirin treatment, sofosbuvir plus ledipasvir is ...
Nov 4, 2014
0
1
After the success of a new drug treatment in adults with hepatitis C infection, a Saint Louis University pediatric researcher is testing the safety and efficacy of the medications in children.
Sep 22, 2014
0
0
Levels of interferon-stimulated genes in the liver and blood could help predict if a patient with hepatitis C will respond to conventional therapy, researchers at Kanazawa University suggest.
May 8, 2014
0
0
Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented today at the International Liver Congress 2014 showed that simeprevir 150 mg once-daily for 12 weeks in combination with peginterferon ...
Apr 12, 2014
0
0
New research announced at the International Liver Congress 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV).
Apr 11, 2014
0
0
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
Jan 15, 2014
0
0
